Greenbrook TMS Announces Dates for Its First Quarter 2022 Financial Results

Rhea-AI Summary

Greenbrook TMS Inc. (NASDAQ: GBNH) will announce its first quarter 2022 operational and financial results on May 13, 2022, after market hours. A conference call will follow on May 16, 2022, at 10:00 a.m. ET, featuring CEO Bill Leonard and CFO Erns Loubser. Interested parties can access the call through a toll-free number or via webcast at www.greenbrooktms.com/investors/events.htm. The company operates 149 treatment centers in the U.S., specializing in Transcranial Magnetic Stimulation therapy.

Positive

• Greenbrook operates 149 treatment centers, enhancing its market presence.
• The company has provided over 790,000 TMS treatments to more than 22,000 patients, indicating strong demand for its services.

Negative

• None.

TORONTO--(BUSINESS WIRE)-- Greenbrook TMS Inc. (TSX: GTMS, NASDAQ: GBNH) (“Greenbrook” or the “Company”), will release its 2022 first quarter operational and financial results after market hours on May 13, 2022.

FIRST QUARTER 2022 CONFERENCE CALL DETAILS:

Bill Leonard, President and Chief Executive Officer, and Erns Loubser, Chief Financial Officer, will host a conference call at 10:00 a.m. (Eastern Time) on May 16, 2022 to discuss the financial results for the quarter.

Dial in Numbers:

Toll Free North America: 1 (866) 521-4909
Toronto: (647) 427-2311

Webcast:

For more information or to listen to the call via webcast, please visit:
www.greenbrooktms.com/investors/events.htm

For those that plan on accessing the conference call or webcast, please allow ample time prior to the call time.

Conference Call Replay:

Toll Free (North America): 1 (800) 585-8367
Toronto: (416) 621-4642
Conference ID: 3459997

The conference call replay will be available from 1:00 p.m. ET on May 16, 2022, until 11:59 p.m. ET on June 16, 2022.

About Greenbrook TMS Inc.

Operating through 149 Company-operated treatment centers, Greenbrook is a leading provider of Transcranial Magnetic Stimulation (“TMS”) therapy, an FDA-cleared, non-invasive therapy for the treatment of Major Depressive Disorder and other mental health disorders, in the United States. TMS therapy provides local electromagnetic stimulation to specific brain regions known to be directly associated with mood regulation. Greenbrook has provided more than 790,000 TMS treatments to over 22,000 patients struggling with depression.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220421005012/en/

For further information please contact:

Glen Akselrod

Investor Relations

Greenbrook TMS Inc.



investorrelations@greenbrooktms.com

1-855-797-4867

Source: Greenbrook TMS Inc.

FAQ

When will Greenbrook TMS release its first quarter 2022 financial results?

Greenbrook TMS will release its first quarter 2022 financial results on May 13, 2022, after market hours.

What time is the Greenbrook TMS conference call for discussing financial results?

The conference call will be held on May 16, 2022, at 10:00 a.m. ET.

How can I listen to the Greenbrook TMS conference call?

You can listen to the conference call by dialing the toll-free number 1 (866) 521-4909 or visiting their website for the webcast.

What services does Greenbrook TMS provide?

Greenbrook TMS provides Transcranial Magnetic Stimulation (TMS) therapy, a non-invasive treatment for Major Depressive Disorder and other mental health disorders.